An Open-label Phase II Study of Lorvotuzumab Mertansine
Status:
Completed
Trial end date:
2017-06-06
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to
control blood cancers that have the CD56 tumor marker. The safety of this drug will also be
studied.